Welcome to our dedicated page for Ir-Med SEC filings (Ticker: IRME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ir-Med’s breakthrough spectroscopy sensors and AI diagnostic software make its SEC disclosures a blend of biotech detail and engineering nuance. Investors reading the Ir-Med Inc annual report 10-K simplified want clarity on clinical trial progress, FDA submissions, and manufacturing scale-up—all tucked inside dense risk factors and footnotes.
Stock Titan removes that friction. Our AI-powered summaries tag every Ir-Med quarterly earnings report 10-Q filing, spotlight R&D burn rates, patent additions, and cash runway. We translate Ir-Med 8-K material events explained into plain language minutes after they post. Need alerts on leadership moves? We stream Ir-Med insider trading Form 4 transactions and every Ir-Med Form 4 insider transactions real-time so you can act on Ir-Med executive stock transactions Form 4 before the market digests them. Ask naturally—"understanding Ir-Med SEC documents with AI" or "Ir-Med proxy statement executive compensation"—and receive concise answers instead of 200-page PDFs.
Here’s how professionals use the page:
- Run Ir-Med earnings report filing analysis to compare sensor unit margins quarter over quarter.
- Monitor board proposals and voting outcomes inside each Ir-Med proxy statement executive compensation section.
- Track regulatory milestones called out in every 8-K without wading through legal jargon.
With all Ir-Med SEC filings explained simply, real-time updates, and AI context you can trust, Stock Titan turns regulatory data into actionable insight.
IR-Med, Inc. reported that it has amended employment terms for its CEO and CFO and is facing significant financial pressures that have delayed required SEC reporting. Effective December 1, 2025, CEO Ran Ziskind moved from a fixed salary to an hourly rate of NIS 37 per hour, which the board may raise up to NIS 300 per hour if a significant funding round is secured. CFO Sharon Levkoviz also shifted from a reduced fixed salary to an hourly rate of NIS 185 per hour.
The company disclosed that due to current financial difficulties it did not file its Q3 2025 Form 10-Q by the deadline. IR-Med is evaluating alternatives to address its liquidity needs and intends to resume timely SEC filings once its financial challenges are resolved, but it gives no assurance on the timing or outcome of these efforts.
FAQ
What is the current stock price of Ir-Med (IRME)?
What is the market cap of Ir-Med (IRME)?
